Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100)).
2021 yr.
Tigerase®
INN: dornase alfa
Description
Indications for use
Articles for specialists
Recombinant human deoxyribonuclease I, a genetically engineered version of a natural human enzyme that cleaves extracellular DNA. The mechanism of the drug is the cleavage of extracellular DNA molecules that accumulate in bronchial secretions due to the breakdown of neutrophils, macrophages and bacterial cells and increase its viscosity.
Dornase alfa is the primary mucolytic drug for the treatment of cystic fibrosis.
The use of dornase alfa in patients with cystic fibrosis promotes:
- Rapid and significant reduction in sputum viscosity
- Significant improvement in external respiration function
- Reducing the risk of upper respiratory tract infection
Generium is the first company in the world to develop and produce dornase alpha biosimilar.
ЛП-005537 от 23.05.2019
-
Read